Ozempic Stomach Paralysis Lawsuit Update

Weight Loss/Diabetes Drug Side Effect Lawsuit

Recently, the pharmaceutical landscape was stirred by the emergence of Ozempic, Trulicity, and Mounjaro. With Ozempic commercials becoming a fixture on television, the airwaves are filled with its catchy jingle and imagery portraying users enjoying an improved quality of life as a result of this prescription drug. However, these diabetes medications have also garnered significant attention for their dangerous side effects.

The diabetes drugs Ozempic and Mounjaro, along with other medications, caught national attention for their off-label use by many people wanting to lose weight. After suffering serious side effects, many users have filed an Ozempic lawsuit to recover the financial losses they are facing.

Ozempic and Mounjaro, Along With Other Medications Such as Wegovy, Trulicity, and Rybelsus, are Harming Thousands of Users

Amid the portrayed image of well-being, reality has taken a darker turn for some obesity medicine users. A surge of more than 10,000 complaints revealed unexpected and severe side effects experienced by individuals who took Ozempic or similar drugs such as Mounjaro or Wegovy. This may be because Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) is a medication designed to raise insulin and lower blood sugar, not cause weight loss.

We are seeing ever-growing anecdotal evidence of a link between these diabetes medications and gastroparesis, also known as paralyzed stomach. Common symptoms of gastroparesis include nausea and vomiting. Further, we continue to hear complaints of severe gastroparesis, visits to the emergency room for abdominal pain, and extremely slow digestion. 

Count on Lawsuit Legal News for Comprehensive Ozempic Gastroparesis Lawsuit Insights

At Lawsuit Legal News, we stand at the forefront of Ozempic lawsuit litigation, diligently reporting on the unfolding developments.

Our adept legal team is already engaged in meticulous case analysis and in-depth research, diligently assembling the foundations for product liability lawsuits on behalf of individuals who, unsuspectingly, injected this potentially dangerous drug into their systems, only to encounter life-altering consequences.

If doctors have prescribed Ozempic or similar medications like Wegovy, Mounjaro, or Rybelsus, and you experienced persistent vomiting, abdominal distress, bloating, acid reflux, or other gastrointestinal afflictions, we can help you. Our dedicated team of product liability injury attorneys is ready to pursue legal recourse against the pharmaceutical manufacturer and recover your Ozempic-related financial losses.

The team of legal professionals at Lawsuit Legal News has more than 120 years of combined legal experience helping more than 40,000 clients who have been injured by someone else’s negligence or companies that produce dangerous products. We have recovered more than $400 million for our deserving clients to help them move forward after serious injuries. Reach out today for a no-obligation free consultation and empower yourself with knowledge about your legal options.

Dissecting an Ozempic Lawsuit: What You Need to Know

Ozempic is a diabetes medicine intended to manage blood sugar levels. Users inject the drug once a week. Ozempic helps your body release insulin, which is what helps sugar enter your cells. Insulin helps keep your blood sugar steady after you eat by controlling how your body releases sugar from the food you eat. 

Ozempic also makes you feel full for longer by slowing the rate at which food leaves your stomach. It reduces the urge to eat by controlling a hormone that makes you feel hungry. But there’s more to the story. 

Studies show that Ozempic can affect the nerves in your stomach, slowing down how your stomach digests food. Sometimes, this can lead to food staying in your stomach for too long, causing problems like a hard mass of food called a bezoar remaining in your stomach or even making you throw up food from days earlier.

When your stomach muscles slow down too much or stop working, it causes stomach paralysis or gastroparesis. The makers of Ozempic and other drugs don’t mention this painful condition in their prescribing or dosing information despite the studies that show these injectable medications are known to slow stomach emptying. 

A Look at Ozempic’s FDA Journey 

The FDA approved Ozempic (with the generic name Semaglutide) in 2017 for treating diabetes. It is administered as a shot once a week in doses of either 0.5 mg or 1 mg. Later, when studies said Ozempic could help people with diabetes and heart problems avoid serious heart issues, the FDA expanded its approval to include cardiovascular indications.

In 2022, the FDA approved a stronger weekly dose because studies showed that Ozempic lowered blood sugar levels into the range recommended by the American Diabetes Association.

All the while, Ozempic ads continued talking about weight loss, but they didn’t mention serious stomach problems like gastroparesis, even though the studies from years earlier revealed stomach paralysis can be a side effect.

What Do We Know About Ozempic’s Potential Side Effects, Including Cyclic Vomiting Syndrome at This Point?

Before starting any medication, users have the right to understand its possible side effects and complications. The potential risks of Ozempic have revealed themselves over the years, yet the maker has not warned potential users about all of these risks.

At the outset, Ozempic’s manufacturer cautioned about several initial side effects, including:

• Inflammation of the pancreas (pancreatitis)
• Changes in vision
• Kidney problems, including kidney failure
• Possible allergic reactions

However, as our comprehension deepens, so does our awareness of the potential risks linked to Ozempic.

We now know that Ozempic can lead to:

• Formation of gallstones
• Sudden inflammation of the gallbladder (cholecystitis)
• Possibility of thyroid tumors or thyroid cancer
• Diabetic retinopathy, a condition impacting the eyes
• Episodes of low blood sugar (hypoglycemia)
• Gastroparesis, the troubling stomach paralysis that is now coming to light

The First Ozempic Lawsuits Addressed Gallbladder Problems

In 2022, mounting medical studies forged a link between Ozempic and gallbladder complications, compelling Novo Nordisk to add a cautionary note about potential gallbladder issues to the drug’s information insert.

Nevertheless, scores of Ozempic users have suffered severe gallbladder troubles, translating to significant financial losses. This predicament gave birth to a slew of Ozempic gallbladder lawsuits filed across the nation.

The Start of Ozempic Gastrointestinal Concerns

In 2020, studies revealed the potential worsening of diabetic gastroparesis symptoms in patients who took Ozempic with a prior history of the condition. Though the precise cause of gastroparesis remains unknown, one-third of the reported cases were traced to uncontrolled diabetes, according to the Cleveland Clinic.

Further investigations cast a spotlight on the medication itself, indicating that its impact on stomach muscles might lead to blockages in the digestive tract that can result in severe stomach problems.

Those gripped by gastroparesis report feeling full after eating a small amount of food, along with acid reflux, persistent nausea, vomiting, stomach and lower GI pain, and diminished appetite.  Not surprisingly, these issues lead to involuntary weight loss.

An article from CNN News found more studies that revealed how GLP-1 agonists, like Ozempic, could intensify diabetic gastroparesis. Unfortunately, pharmaceutical disclosures did not mention these revelations, and Novo Nordisk chose not to notify physicians about this lurking threat of severe gastrointestinal events or revise its prescription guidelines.

Breaking News: Recent Ozempic Articles Reveal the Extent of Stomach Paralysis Cases

July 2023 witnessed a cascade of patient safety stories, chronicling the horror stories of Ozempic and Wegovy users grappling with gastroparesis. In CNN’s comprehensive exposé, several individuals who were prescribed GLP-1 agonist medications, including Ozempic and Wegovy, found themselves suffering from gastroparesis. 

During this same time, the FDA claimed it could not definitively establish a direct causal relationship between the drugs and stomach paralysis, so it refrained from mandating Novo Nordisk to undertake any immediate actions.

In response to CNN’s inquiries, Novo Nordisk issued this statement: “Gastrointestinal (GI) events are well-known side effects of the GLP-1 class. For semaglutide, the majority of GI side effects are mild to moderate in severity and of short duration. GLP-1’s are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications. Symptoms of delayed gastric emptying, nausea, and vomiting are listed as side effects.” 

While the product’s prescribing information acknowledges nausea and vomiting and delayed gastric emptying, these references revolve around the absorption of other medications while taking Ozempic, not the serious side effect complications at hand and the potential of severe gastrointestinal events.

Has Wegovy Done Any Clinical Testing? 

Since Wegovy is actually prescribed as a weight loss drug and administered at twice the dosage of Ozempic, clinical trials of this medication have unveiled intriguing insights. A study of Wegovy users revealed that nearly 44 percent of Wegovy recipients reported nausea, with almost 25 percent experiencing vomiting—both telltale symptoms of gastroparesis and other severe stomach issues.  There is also anecdotal evidence this medication causes an issue called delayed gastric emptying.

Similar trials featuring Ozempic users taking the lower prescribed dosage showed approximately 20 percent of Ozempic users reported nausea, and 10 percent cited vomiting as common side effects.

Ozempic Maker Continues to Promote Weight Loss Benefits While Ignoring Growing Reports of Medical Complications

Although Ozempic is only FDA-approved for diabetes management, Novo Nordisk continues to extoll Ozempic’s weight loss virtues in advertising campaigns. This marketing thrust has used celebrities to vouch for Ozempic’s weight-shedding prowess on social media.

Physicians may legally prescribe Ozempic “off-label” for weight loss, and they have veered away from its primary diabetic focus in response to pressure from their patients.

In early 2023, Ozempic appeared on the FDA’s Drug Shortage List because of the escalating demand for the drug among those striving to shed pounds. Because the drug is in short supply, the maker can increase its price because anxious users will pay more. This translates into substantial gains for Novo Nordisk, even as users grapple with grave medical complexities, transformative life conditions, and formidable financial setbacks.

Untangling the Legal Basis of the Ozempic Stomach Paralysis Lawsuit

In what is likely the first of many Ozempic stomach paralysis lawsuits, the initial case was filed by a 44-year-old woman from Louisiana. Named defendants include Novo Nordisk (the creator of Ozempic) and Eli Lilly and Company (the maker of Mounjaro). The plaintiff’s complaint described how she took Ozempic for a year, ending in July 2023. Subsequently, she started taking Mounjaro for similar medical purposes.

At the core of her lawsuit, she asserts that both medications created severe gastrointestinal problems, including relentless vomiting and acute stomach distress. She alleges her condition was so violent she lost teeth as a result. Her numerous gastrointestinal episodes also required her to seek multiple hospitalizations.

The complaint is based on the legal argument that the drug manufacturers failed to provide any disclosure regarding the potential for serious gastrointestinal upheaval within the drugs’ prescribing information. Also, the complaint alleges the makers failed to warn about the potential for gastroparesis. The lawsuit pivots upon legal grounds of inadequate warning, failure to warn, and breach of warranty.

While this first lawsuit only names the pharmaceutical manufacturers as defendants, a cascade of future Ozempic claims may implicate not just the drug makers but also distributors and retailers.

Trust Lawsuit Legal News For the Latest Information About Mass Tort and Dangerous Drug Lawsuits

At Lawsuit Legal News, we are proud of our track record, which reveals our tenacity and experience spanning an array of dangerous drug litigations.

We are the go-to resource for the latest details about: 

• Tylenol autism lawsuits
• Tepezza hearing loss claims 
• Elmiron vision loss lawsuits 
• EzriCare Eye Drop claims
• Other mass tort litigation

The team of legal professionals at Lawsuit Legal News brings an arsenal of skills, experience, and resources needed to challenge greedy corporate pharmaceutical giants and fight for the legal rights of individuals harmed by these companies while pursuing rightful compensation.

Are You Ready to Bring an Ozempic Stomach Paralysis Lawsuit?

We expect a deluge of Ozempic gastrointestinal lawsuits spurred by the popularity of this medication for weight loss despite the potential medical implications. The legal professionals at Lawsuit Legal News stand prepared to safeguard consumers from profit-driven conglomerates. If Ozempic, Wegovy, or other GLP-1 medications injured you, you have rights. Contact our dedicated legal staff at 866-467-0943 or complete our contact form for your free consultation today.

Answers to Frequently Asked Questions About the Ozempic Lawsuit

Our Clients Share Their Stories…

“Very Good Experience. I was with another attorney who did not return my phone calls, messages, or help me with any questions and had no advice as far as who to go to for the medical attention I needed. I found Matt and got everything I needed, my questions answered, and he was very fast , professional & helpful.”

Arianna

“They took care of me as if I was a member of their family and for that I cannot be thankful enough. … I am so happy to finally be moving on with my life and am thankful they allowed me the opportunity to do so in the best way possible!”

Client